Weekly Digest - November 2026

Weekly Digest - November 2026

16 November 2026: OBI Pharma signs collaboration and license agreement with Novartis 

  • OBI Pharma entered into a collaboration and license agreement with Novartis Pharma AG to develop next-generation ADC using OBI’s proprietary ADC platform technologies and novel payloads. Novartis receives exclusive worldwide rights to OBI’s related patents and know-how for selected, undisclosed payload classes, with an option to expand the agreement to additional payload classes
  • The collaboration is at the platform development stage, with no specific ADC candidate, clinical trial, NCT number or clinical efficacy data disclosed. OBI and Novartis will evaluate novel linker approaches in combination with Novartis’s proprietary payloads to generate next-generation ADC candidates
  • The collaboration aims to develop differentiated ADCs incorporating novel payload classes and optimized linker technologies, potentially expanding therapeutic approaches for cancer patients. however, the specific tumour indications, molecular targets and intended patient populations have not yet been disclosed
  • The collaboration focuses on next-generation  ADC using OBI’s proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI® and GlycOBI DUO®. OBI will also evaluate novel linker approaches with Novartis payloads to optimize ADC development. specific antibody targets, payload classes and linker chemistries remain undisclosed
  • The agreement includes a $30 million upfront payment, with potential development, regulatory and commercial milestone payments bringing the total deal value to more than $2 billion, in addition to tiered royalties on future net sales. collaboration strengthens OBI’s position as an ADC technology partner and validates the commercial potential of its proprietary platforms 

For full story click  here

Share this